Loading
A phase 3 trial of Durvalumab, Carboplatin, Gemcitabine + cisplatin, Gemcitabine, Cisplatin and Pemetrexed in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) is a phase 3 interventional study registered as NCT03003962 by AstraZeneca, with 669 participants enrolled, started 2017-01-02 and due to reach its primary completion in 2022-10-27. Interventions recorded: Durvalumab (MEDI4736), Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin and Pemetrexed + carboplatin. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
669 enrolled.
95% CI 12.2 to 16.9; Figures from the ClinicalTrials.gov results section (first posted 2023-12-26), not from a publication · 95% CI 10.1 to 14.7
Source95% CI 12.6 to 17.2; Figures from the ClinicalTrials.gov results section (first posted 2023-12-26), not from a publication · 95% CI 13.1 to 16.8
SourceFigures from the ClinicalTrials.gov results section (first posted 2023-12-26), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Survival (OS)primary | Durvalumab | 335 | 14.6 months | 0.84 (0.706 to 0.989) | 0.037 | link |
| Platinum-based SoC | 334 | 12.8 months | ||||
| OS in Participants With LREMprimary | Durvalumab | 278 | 14.6 months | 0.96 (0.793 to 1.151) | 0.628 | link |
| Platinum-based SoC | 271 | 15 months | ||||
| Objective Response Rate (ORR) as Per RECIST 1.1 Using Investigator Assessment | Durvalumab | 335 | 37.6% | - | - | link |
| Platinum-based SoC | 334 | 37.4% |
Shares Gemcitabine + cisplatin, Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.
Shares Gemcitabine + cisplatin, Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.
Shares Gemcitabine + cisplatin, Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.
Shares Pemetrexed, Durvalumab, AstraZeneca, Cisplatin and the tag pipeline.
Shares Pemetrexed, Durvalumab, AstraZeneca, Cisplatin and the tag pipeline.
Shares Durvalumab, Gemcitabine, AstraZeneca, Cisplatin and the tag pipeline.
Shares Durvalumab, Gemcitabine, AstraZeneca, Cisplatin and the tag pipeline.
Shares Gemcitabine + cisplatin, Durvalumab, Gemcitabine, Cisplatin and the tag pipeline.